BHVN
Biohaven Ltd. NYSE Listed Sep 23, 2022$13.57
-0.37%
vs $13.62
Mkt Cap $1.5B
52w Low $7.79
56.0% of range
52w High $18.11
50d MA $10.28
200d MA $11.57
P/E (TTM)
-2.0x
EV/EBITDA
—
P/B
28.1x
Debt/Equity
5.4x
ROE
-1418.8%
P/FCF
-2.4x
RSI (14)
68.70
ATR (14)
$0.91
Beta
3.62
50d MA
$10.28
200d MA
$11.57
Avg Volume
3.0M
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
215 Church Street · New Haven, CT 06510 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | -1.22 | -1.21 | +0.8% | 11.81 | -3.2% | -9.7% | -0.6% | -2.8% | -3.8% | +2.9% | — |
| Nov 10, 2025 | AMC | -1.91 | -1.64 | +14.1% | 7.79 | -0.8% | +9.4% | -6.7% | +1.6% | +2.7% | -0.4% | — |
| Aug 11, 2025 | AMC | -1.94 | -1.94 | +0.0% | 13.41 | +1.9% | +0.4% | +6.8% | -1.1% | +10.4% | +1.9% | — |
| May 12, 2025 | AMC | -1.67 | -2.17 | -29.9% | 20.56 | +0.9% | -5.1% | +0.8% | -19.5% | +1.3% | -1.7% | — |
| Mar 3, 2025 | AMC | -1.56 | -1.85 | -18.6% | 32.06 | -1.4% | -2.2% | -1.3% | -1.8% | -1.8% | -7.5% | — |
| Nov 12, 2024 | AMC | -1.70 | -1.70 | +0.0% | 50.36 | +2.9% | -2.6% | -0.8% | -8.8% | +2.3% | +2.0% | — |
| Aug 8, 2024 | AMC | -1.72 | -3.64 | -111.6% | 36.62 | -1.3% | +6.3% | -5.0% | +6.3% | -3.1% | +3.0% | — |
| May 9, 2024 | AMC | -1.50 | -2.20 | -46.7% | 41.36 | -3.0% | -13.7% | -5.4% | +10.2% | -0.4% | +3.7% | — |
| Feb 29, 2024 | AMC | -1.41 | -1.81 | -28.4% | 48.14 | -1.4% | +2.9% | +13.8% | +4.0% | -0.9% | -0.1% | — |
| Nov 14, 2023 | AMC | -1.33 | -1.50 | -12.8% | 29.78 | -0.5% | -2.5% | +2.1% | +1.4% | +1.7% | -3.5% | — |
| Jul 31, 2023 | AMC | -1.24 | -1.32 | -6.5% | 19.88 | -0.9% | -1.2% | -1.9% | -0.7% | +2.8% | -2.3% | — |
| May 12, 2023 | AMC | -1.39 | -1.03 | +25.9% | 13.61 | +1.5% | +6.9% | -4.7% | +1.8% | -1.8% | +1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | Citigroup | Maintains | Buy → Buy | — | $9.62 | $9.54 | -0.8% | +1.9% | -6.6% | +1.2% | +1.3% | +0.1% |
| Mar 11 | TD Cowen | Maintains | Buy → Buy | — | $10.27 | $10.58 | +3.0% | +1.9% | -5.3% | -3.3% | +0.6% | -1.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.67 | $10.76 | +0.8% | -0.6% | -2.8% | -3.8% | +2.9% | +0.6% |
| Mar 3 | RBC Capital | Maintains | Outperform → Outperform | — | $11.81 | $11.43 | -3.2% | -9.7% | -0.6% | -2.8% | -3.8% | +2.9% |
| Jan 21 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $12.68 | $13.85 | +9.2% | +1.5% | +6.9% | -1.8% | -5.7% | -0.5% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $9.93 | $9.96 | +0.3% | -3.1% | +22.0% | -3.2% | -2.2% | +6.6% |
| Dec 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.81 | $9.67 | -10.5% | +3.1% | +3.5% | +0.9% | -3.0% | -4.0% |
| Dec 3 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $8.83 | $8.50 | -3.7% | +3.3% | +5.4% | -0.6% | +10.4% | -0.6% |
| Nov 26 | UBS | Downgrade | Buy → Neutral | — | $9.41 | $9.00 | -4.4% | +0.7% | +5.8% | -7.1% | -5.3% | +3.3% |
| Nov 20 | JP Morgan | Maintains | Overweight → Overweight | — | $9.46 | $9.67 | +2.2% | +1.8% | +0.6% | -0.1% | -2.8% | +0.7% |
| Nov 18 | BTIG | Maintains | Buy → Buy | — | $8.27 | $8.25 | -0.2% | +14.3% | +0.1% | +1.8% | +0.6% | -0.1% |
| Nov 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.27 | $8.25 | -0.2% | +14.3% | +0.1% | +1.8% | +0.6% | -0.1% |
| Nov 13 | Citigroup | Maintains | Buy → Buy | — | $7.95 | $7.84 | -1.4% | +1.6% | +2.7% | -0.4% | +14.3% | +0.1% |
| Nov 6 | Bernstein | Downgrade | Outperform → Market Perform | — | $8.34 | $8.61 | +3.2% | +2.3% | -3.2% | -5.7% | +9.4% | -6.7% |
| Nov 6 | BTIG | Maintains | Buy → Buy | — | $8.34 | $8.61 | +3.2% | +2.3% | -3.2% | -5.7% | +9.4% | -6.7% |
| Nov 6 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $8.34 | $8.61 | +3.2% | +2.3% | -3.2% | -5.7% | +9.4% | -6.7% |
| Nov 5 | William Blair | Downgrade | Outperform → Market Perform | — | $13.95 | $8.40 | -39.8% | -40.2% | +2.3% | -3.2% | -5.7% | +9.4% |
| Nov 5 | TD Cowen | Maintains | Buy → Buy | — | $13.95 | $8.40 | -39.8% | -40.2% | +2.3% | -3.2% | -5.7% | +9.4% |
| Sep 16 | UBS | Maintains | Buy → Buy | — | $13.74 | $13.70 | -0.3% | -1.8% | +9.0% | +5.6% | -7.7% | +3.7% |
| Aug 19 | BTIG | Maintains | Buy → Buy | — | $16.01 | $15.89 | -0.7% | -4.7% | -3.6% | -0.1% | +6.3% | -4.3% |
| Aug 12 | Baird | Maintains | Outperform → Outperform | — | $13.41 | $13.66 | +1.9% | +0.4% | +6.8% | -1.1% | +10.4% | +1.9% |
| Aug 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.41 | $13.66 | +1.9% | +0.4% | +6.8% | -1.1% | +10.4% | +1.9% |
| Aug 12 | Leerink Partners | Maintains | Outperform → Outperform | — | $13.41 | $13.66 | +1.9% | +0.4% | +6.8% | -1.1% | +10.4% | +1.9% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.41 | $13.66 | +1.9% | +0.4% | +6.8% | -1.1% | +10.4% | +1.9% |
| Aug 12 | BofA Securities | Maintains | Buy → Buy | — | $13.41 | $13.66 | +1.9% | +0.4% | +6.8% | -1.1% | +10.4% | +1.9% |
| Jun 18 | JP Morgan | Maintains | Overweight → Overweight | — | $14.56 | $14.58 | +0.1% | -1.2% | +0.5% | +0.0% | +2.1% | -3.0% |
| May 19 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $16.02 | $15.45 | -3.6% | -1.7% | +3.2% | -3.4% | -1.7% | +1.4% |
| May 13 | RBC Capital | Maintains | Outperform → Outperform | — | $20.56 | $20.75 | +0.9% | -5.1% | +0.8% | -19.5% | +1.3% | -1.7% |
| Apr 28 | Baird | Maintains | Outperform → Outperform | — | $19.84 | $19.84 | +0.0% | +9.6% | +0.6% | +1.1% | +1.5% | +1.8% |
| Mar 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.40 | $30.40 | +0.0% | -1.8% | -7.5% | +6.4% | +0.0% | -4.0% |
| Mar 5 | JP Morgan | Maintains | Overweight → Overweight | — | $31.37 | $31.87 | +1.6% | -1.3% | -1.8% | -1.8% | -7.5% | +6.4% |
| Mar 4 | RBC Capital | Maintains | Outperform → Outperform | — | $32.06 | $31.61 | -1.4% | -2.2% | -1.3% | -1.8% | -1.8% | -7.5% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.06 | $31.61 | -1.4% | -2.2% | -1.3% | -1.8% | -1.8% | -7.5% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.44 | $40.98 | -1.1% | -5.6% | -8.0% | -1.8% | +2.6% | -0.3% |
| Dec 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.44 | $40.98 | -1.1% | -5.6% | -8.0% | -1.8% | +2.6% | -0.3% |
| Dec 4 | RBC Capital | Maintains | Outperform → Outperform | — | $43.68 | $43.95 | +0.6% | +5.4% | -5.6% | +3.0% | -3.5% | -1.5% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.23 | $45.45 | +0.5% | +4.5% | -1.9% | -0.8% | -2.8% | -2.4% |
| Nov 25 | RBC Capital | Maintains | Outperform → Outperform | — | $45.59 | $40.80 | -10.5% | -0.8% | +4.5% | -1.9% | -0.8% | -2.8% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.04 | $48.98 | -0.1% | -0.8% | -8.8% | +2.3% | +2.0% | +1.1% |
| Nov 13 | RBC Capital | Maintains | Outperform → Outperform | — | $50.36 | $51.81 | +2.9% | -2.6% | -0.8% | -8.8% | +2.3% | +2.0% |
| Nov 13 | TD Cowen | Maintains | Buy → Buy | — | $50.36 | $51.81 | +2.9% | -2.6% | -0.8% | -8.8% | +2.3% | +2.0% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $36.97 | $37.00 | +0.1% | +6.3% | -3.1% | +3.0% | -1.8% | +3.0% |
| Jun 18 | RBC Capital | Maintains | Outperform → Outperform | — | $32.99 | $33.22 | +0.7% | -0.7% | +2.0% | +0.4% | +3.5% | +0.7% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.17 | $33.49 | +1.0% | +6.2% | -0.4% | -1.5% | -3.5% | +4.3% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.69 | $35.46 | -0.6% | -5.4% | +10.2% | -0.4% | +3.7% | -2.8% |
| Apr 23 | UBS | Maintains | Buy → Buy | — | $38.33 | $40.54 | +5.8% | +3.3% | -2.2% | -0.5% | +1.1% | +2.2% |
| Apr 9 | RBC Capital | Maintains | Outperform → Outperform | — | $51.41 | $51.62 | +0.4% | +1.1% | -1.8% | +4.8% | -0.8% | -15.7% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.54 | $51.50 | +4.0% | +13.8% | +4.0% | -0.9% | -0.1% | -0.1% |
| Mar 1 | RBC Capital | Maintains | Outperform → Outperform | — | $48.14 | $47.48 | -1.4% | +2.9% | +13.8% | +4.0% | -0.9% | -0.1% |
| Mar 1 | TD Cowen | Maintains | Outperform → Outperform | — | $48.14 | $47.48 | -1.4% | +2.9% | +13.8% | +4.0% | -0.9% | -0.1% |
No insider trades available.
8-K · 7.01
! Medium
Biohaven Ltd. -- 8-K 7.01: Regulation FD Disclosure
Biohaven Ltd. released positive clinical biomarker and patient data on May 27, 2026, potentially supporting its drug development pipeline and investor confidence.
May 27
8-K
Biohaven Ltd. -- 8-K Filing
Biohaven's experimental drug BHV-1300 demonstrated potent IgG reduction up to 87% in early testing, positioning the company to advance a pivotal Graves' disease trial in late 2026.
Mar 2
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 18
All ↗
Valuation
Market Cap
$1.46B
Enterprise Value
$1.42B
P/E (TTM)
-1.98x
Forward P/E
—
PEG Ratio
0.06x
P/B
28.05x
P/S
—
P/FCF
-2.39x
EV/EBITDA
—
Shares Out
107.6M
Financials (TTM)
Revenue
$0
Net Income
-$738.8M
EBITDA
-$727.5M
Free Cash Flow
-$610.2M
Op Cash Flow
-$609.4M
EPS Basic
$-6.86
EPS Diluted
$-6.86
EPS Forward
$-2.97
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$451.4M
Total Liab.
$399.4M
Total Equity
$52.1M
Cash
$319.1M
LT Debt
$278.9M
Book Value/Sh
$0.48
Debt/Equity
5.36x
Current Ratio
3.18
Quick Ratio
3.18
Returns & Growth
ROE
-1418.8%
ROA
-163.7%
ROIC
-222.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+26.1%
Price Returns
2W
+22.1%
1M
+14.8%
3M
-4.4%
6M
+9.8%
12M
-25.7%
Technicals
52W High
$18.11
52W Low
$7.79
50d MA
$10.28
200d MA
$11.57
RSI (14)
68.70
ATR (14)
$0.91
Beta
3.62
Avg Volume
3.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$21.29
High
$42.00
Low
$10.00
Median
$22.00
Data updated apr 24, 2026 9:36pm
· Source: financialmodelingprep.com